Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry
Takeshi Harada, Ariel López-Chávez, Liqiang Xi et al. · Oncogene · 2010
Cited by 38 works. doi:10.1038/onc.2010.545
Authors
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Image processing with ImageJ
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
- Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib